T HE renin-angiotensin system plays a central role in the regulation of extracellular fluid volume and blood pressure. Angiotensins I and II are generated from angiotensinogen (renin substrate) by enzymatic processing by renin and converting enzyme. Plasma angiotensinogen is a glycoprotein of hepatic origin.' Although plasma renin is believed to act on circulating angiotensinogen to generate angiotensin I, recent findings have hinted at a more complex organization of the renin-angiotensin system. Synthesis of angiotensinogen is not restricted to the liver, since messenger RNA for angiotensinogen has been localized in the brain 2 
"
4 and other organs. 3 " 3 We 6 have found a binding site for angiotensinogen in adrenoglomerulosa cells. Angiotensin II can be generated directly from angiotensinogen by cathepsin G. 7 Finally, angiotensinogen belongs to a superfamily of proteins,' most of which are serine protease inhibitors, suggesting that angiotensinogen may act as a protease inhibitor. 9 A variety of experimental approaches are needed to explore these issues, and pure angiotensinogen will be useful in some of these experiments.
The present report details the purification of canine angiotensinogen. The procedure is relatively straightforward, identifies two molecular weight forms and four isoforms of angiotensinogen, and allows independent recovery of the four isoforms.
Materials and Methods
Adult male mongrel dogs (Vrand, Millville, NY, USA) were anesthetized with pentobarbital and mechanically ventilated. Through flank in incisions and retroperitoneal dissection, the renal arteries and veins were ligated and both kidneys removed. Through a femoral artery, a catheter was introduced into the aorta. Since the increase in the concentration of plasma angiotensinogen evoked by bilateral nephrectomy is completed in 8 hours, 10 the dogs were maintained under anesthesia for this period. The animals were then exsanguinated by collecting blood through the femoral artery catheter. Blood was collected in bottles containing Na2 EDTA at a final concentration of 0.2%, and the plasma was separated by centrifugation. All procedures were done in accordance with the guidelines of the Institutional Animal Care and Use Committee.
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HYPERTENSION VOL 11, No 1, JANUARY 1988 (radioimmunoassay grade, Sigma) was used as a standard. Angiotensinogen was determined by enzymatic assay. Samples were incubated at 37°C for 1 hour in 0.1 M citrate buffer, pH 6.5, containing 0.04 U of renin and 2.5 mM phenylmethylsulfonyl fluoride (PMSF). Liberated angiotensin I was measured by radioimmunoassay as described. 12 
Purification of Angiotensinogen
The purification procedure consisted of five purification steps.
Step I. Ammonium Sulfate Precipitation At 4°C, plasma was diluted with equal volumes of distilled water in the presence of 2 mM PMSF and 5 mM sodium tetrathionate. Silicic acid (Aerosil 200, Degussa, Teterboro, NJ, USA), was added to the mixture, as described by Hilgenfeldt and Hackenthal. 13 Solid ammonium sulfate was then added, and a protein pellet between 35 and 55% saturation was obtained by centrifugation. The pellet was placed inside dialysis tubing and dialyzed for 18 hours against 5 L of water containing 10 mM Na 2 EDTA, 2 mM PMSF, and 5 mM sodium tetrathionate. Next, the protein solution was dialyzed for 8 hours against 5 L of the buffer used in the second step.
Step 2. Blue Dextran-Sepharose Chromatography
As described by Tewksbury et al., 14 at 4°C, a blue dextran-Sepharose (Affi-gel blue, Bio-Rad) column (5 X 50 cm) was equilibrated with 0.05 M Tris HC1, pH 8.0, with 0.1 M NaCl, 10 mM EDTA, 2 mM PMSF, and 5 mM sodium tetrathionate. After application into the column, the protein solution was eluted with the same buffer into 16-ml fractions. The fractions with the highest specific activity were pooled and concentrated by ultrafiltration to 50 ml with a PM 30 Amicon membrane (Lexington, MA, USA). The protein mixture was then dialyzed for 18 hours at 4°C against 5 L of the buffer used for the third step.
Step 3. Cellulose-Ion Exchange Chromatography
As described by Tewksbury et al. , 14 the protein mixture was introduced at 4°C into a diethylaminoethyl (DEAE)-Sephacel (Pharmacia Fine Chemicals, Uppsala, Sweden) column (5 X 30 cm) equilibrated with 0.05 M Tris HC1, pH 8.0, containing 0.1 M NaCl. Fractions of 15 ml were eluted with the same buffer, and the fractions with the highest specific activity were pooled. They were then concentrated to 50 to 100 ml with a PM 30 Amicon membrane and twice dialyzed against 6 L of distilled water for 8 hours. The protein mixture was aliquoted in tubes containing 12 /ig of angiotensin I equivalents and lyophilized.
Step 4. Hydrophobic Interaction Chromatography
A prepacked Phenyl-Superose HR 5/5 column (Pharmacia) was equilibrated at room temperature with 0.05 M ammonium bicarbonate, pH 8.0, with 1.7 M ammonium sulfate. Aliquots (0.5-1.5 mg protein) of the protein mixture obtained from the DEAE-Sephacel chromatography were dissolved in 1 ml of 0.05 M ammonium bicarbonate, pH 8.0, with 1.7 M ammonium sulfate and were injected into the Phenyl-Superose column. Injection and elution of the sample were performed in the fast protein liquid chromatography (FPLC) system (Pharmacia). The column was eluted with a linear descending gradient of ammonium sulfate from 1.7 to 0 M in 0.05 M ammonium bicarbonate, pH 8.0. Fractions of 1 ml were obtained, and all fractions containing angiotensinogen were pooled and concentrated to dryness with a Speed Vac concentrator (Savant Instruments, Farmingdale, NY, USA).
Step 5. Chromatofocusing
The dried fractions containing angiotensinogen from the previous purification step were equilibrated with 0.025 M bis-Tris buffer, pH 6.3, by recovering the pellets with 2.5 ml of this buffer and eluting them with the same buffer through a PD-10 Sephadex 25 (Pharmacia) disposable column. The protein sample was then introduced with the FPLC system into a prepacked chromatofocusing column (Mono P HR 5/20, Pharmacia) equilibrated, at room temperature, with 0.025 M bis-Tris buffer, pH 6.0. A pH gradient was generated by eluting the column with 4% (vol/vol) Polybuffer 74 (Pharmacia), pH 4.0.
Sodium Dodecyl Sulfate-Polyacrylamide Gel Electrophoresis
Protein samples were incubated at 90 °C for 1 minute in 62.5 mM Tris HC1, pH 6.8, with 3% sodium dodecyl sulfate (SDS), 5% (vol/vol) 2-mercaptoethanol and subjected to SDS-polyacrylamide gel electrophoresis (SDS-PAGE) on 5 to 15% gradient acrylamide gels. 15 To visualize proteins, gels were stained with Coomassie brilliant blue R-250 or the silver stain method of Merril et al. 16 
Isoelectric Focusing
The fraction with the highest specific activity from each one of the two peaks of angiotensinogen eluting from the Phenyl-Superose column were pooled. Then, 5 fig of angiotensinogen of this sample was radioiodinated with lactoperoxidase and glucose oxidase (New England Nuclear radioiodination system, Boston, MA, USA). After separation of 125 I-angiotensinogen from free iodine by filtration with Sephadex G15 (Pharmacia), 123 I-angiotensinogen was analyzed by isoelectric focusing.
Isoelectric focusing gels were prepared as follows: 4.85% acrylamide (ICN Biomedical, Costa Mesa, CA, USA), 0.15% bis-acrylamide (Bio-Rad), 6.33% (vol/vol) Pharmalyte 2.5 to 6.5 pH interval mixture (Pharmacia), 13% (vol/vol) glycerol, and 100 fx\ N'^V'-tetramethylenediamine (Bio-Rad). After deaerating and adding 666 fi\ of ammonium persulfate (22.8 mg/ml), the solution was placed in glass tubes measuring 10 cm in height. After polymerization, the gels were placed in an electrophoresis apparatus cooled to 10°C. The lower (anode) chamber was filled with 0.01 M iminodiacetic acid, while the upper (cathode) cham-CANINE ANGIOTENSINOGEN/0/iver 23 ber was filled with 0.01 M histidine. An aliquot of 123 Iangiotensinogen in 150 (A\ of 30% sucrose was placed on top of a gel. Gels with isoelectric focusing standards (low calibration kit, Pharmacia) were also prepared. Gels were focused at 250 V overnight and at 500 V for 1 hour at the end of the run. The gel containing l23 I-angiotensinogen was sliced at 1-mm intervals, and the slices were eluted in individual tubes with 250 fi\ of 10 mM K G . The tubes were counted in a gamma counter, and their pH was measured with a conventional pH electrode at 22 °C.
Amino Terminal Sequence Analysis
A 500-pmol sample of angiotensinogen was dissolved in 150 fil of 30% trifluoroacetic acid and loaded onto an Applied Biosystems 470A gas phase sequencer equipped with a Model 120A PTH analyzer (Applied Biosystems, Foster City, CA, USA) and sequenced to 15 cycles following directions recommended by the manufacturer. Table 1 , pure canine angiotensinogen was obtained after an 800-fold purification by the fivestep purification procedure. The angiotensin I content of the final preparation was the theoretical maximum of 24 /xg/mg protein of pure angiotensinogen. In four runs, the angiotensin I content of the final preparation averaged 23.8 ± 1.2 (SD) /ig/mg protein. The elution profiles of the protein mixture through the Affi-gel blue and DEAE-Sephacel columns are shown in Figures 1 and 2 , respectively. In both instances, canine angiotensinogen eluted as a single peak. Of note is that, although canine angiotensinogen, like rat 17 and human 18 angiotensinogen, is an acidic protein (as will be discussed), it eluted from DEAE-Sephacel with an isocratic elution at pH 8.0. Isocratic elution in DEAESephacel resulted in a very broad peak of angiotensinogen, but it increased the purity of the preparation fourfold. Phenyl-Superose (Figure 3 ) proved very effective in purifying canine angiotensinogen (see Table 1 with excellent recovery of the injected sample (85%). Moreover, Phenyl-Superose separated angiotensinogen into two peaks (see Figure 3) , suggesting that this protein contains two forms with different hydrophobicity.
Results

As shown in
SDS-PAGE analysis of the protein mixture after each of the first four purification steps is shown in Figure 4 . Proteins with an apparent molecular weight of approximately 57,000 were successively enriched after each step. The protein sample after Phenyl-Superose chromatography (see Figure 4 , Lane 4) re- Summary of one of four purification runs. The recovery estimates of Steps 1 through 3 refer to the overall recovery of the initial angiotensinogen. Steps 4 and 5 were performed by injections of protein aliquots into the Phenyl-Superose and Mono P columns run in the fast protein liquid chromatography system. Ang I = angiotensin I.
•Amount of aliquot. tThe recovery estimates of these two steps refer to the individual recoveries of the angiotensinogen injected into each column. 
FIGURE 2. Elution profile from cellulose-ion exchange chromatography. Protein was loaded on a diethylaminoethyl-Sephacel column in 0.05 M Tris HCl buffer, pH 8.0 (see Materials and Methods for details). Column was run with the same buffer at a flow rate of 150 mllhr and eluted into 15-ml fractions.
vealed two main, closely spaced bands with apparent molecular weights of 58,000 and 56,000 and a few contaminant proteins. This finding suggests that canine angiotensinogen has two molecular weight forms. To determine whether the different molecular weight forms of angiotensinogen corresponded to the two peaks of this protein eluting from the Phenyl-Superose column, SDS-PAGE analysis of separated samples from these two peaks was performed. As shown in the inset in Figure 3 , both molecular weight forms of angiotensinogen were present in both peaks.
In the final purification step, the fractions containing angiotensinogen that eluted from Phenyl-Superose chromatography were chromatofocused in a shallow pH gradient generated by eluting the Mono P column with 4% Polybuffer 74, pH 4.0. As shown in Figure 5 , four isoforms of angiotensinogen eluted from the column (arrows). The pH at which the four peaks of angiotensinogen eluted averaged 4.32 ± 0.06 (SE), 4.23 ±0.06', 4.15 ± 0 . 0 6 , and 4.04 ± 0 . 0 7 (n = 6). Each of these peaks yielded the maximal theoretical content of angiotensin I of pure angiotensinogen (24 fig of angiotensin I/mg protein). Figure 6 shows silver staining of an SDS-PAGE gel of the four isoforms of canine angiotensinogen. Note that the high molecular weight form (58,000) eluted in the four peaks (see Lanes 1^4 in Figure 6 ), whereas the low molecular weight form (56,000) eluted in the two peaks with higher isoelectric points (see Lanes 1 and 2 in Figure 6 ).
Although chromatofocusing revealed four isoforms of canine angiotensinogen, the exact isoelectric points of these forms may differ somewhat from their elution pH, because nonspecific interactions with the column may result in elution of the protein at a pH that differs from its isoelectric point. Indeed, isoelectric focusing of purified l25 I-angiotensinogen showed four isoforms (Figure 7 ), but their isoelectric points (4.69, 4.60, 4.54, and 4.48) were about 0.4 pH U higher than the pH at which the four isoforms eluted during chromatofocusing.
The overall recovery of the first three purification steps was 14%. The last two purification steps, performed with prepacked columns and small protein samples, gave excellent rates of recovery: about 85% for the Phenyl-Superose column and about 100% for the Mono P column. From these values an overall rate of recovery for the purification procedure of approximately 12% can be estimated.
Analysis of the NH 2 -terminal sequence of the first 15 amino acids of angiotensinogen revealed the following sequence: 
Discussion
The five-step procedure described here allowed the isolation of canine angiotensinogen. This protein was purified from plasma obtained from dogs that had undergone bilateral nephrectomy because nephrectomy increases angiotensinogen concentration in plasma and decreases plasma renin activity. 10 The purification strategy used ammonium sulfate firactionation followed by chromatography with blue dextran-Sepharose and ion-exchange chromatography, two purification steps described by Tewksbury et al.
14 to purify human angiotensinogen and used by Bouhnik et al. 17 to isolate rat angiotensinogen. The final two steps that we used differed notably from other purification procedures and made use of the FPLC system and prepacked columns. Hydrophobic interaction chromatography with PhenylSuperose proved very effective. Tewksbury et al." have shown that human angiotensinogen binds to Phenyl-Superose, and canine angiotensinogen bound tightly to this gel. This finding indicates that canine angiotensinogen possesses a hydrophobic region that is exposed in 1.7 M ammonium sulfate. Moreover, elution from Phenyl-Superose separated canine angiotensinogen into two peaks, suggesting the existence of two molecular forms of different hydrophobicity. Finally, since angiotensinogen of several species 13 ' l8> M is known to contain several isoforms, chromatofocusing was used as the next purification step. This procedure yielded four distinct peaks containing the maximal theoretical content of angiotensin I of pure angiotensinogen (approximately 24 fig of angiotensin I/mg protein) and showed no contaminant bands when examined by SDS-PAGE (see Figure 6) .
The overall purification from plasma was 800-fold with a recovery rate of about 12%. This rate was made possible by the excellent recoveries of the two chromatographic steps used with the FPLC system (Phenyl-Superose and Mono P columns), and despite that, recovery rates of the first three purification steps were, by design and in order to maximize the rise in specific activity, quite low.
Analysis of the NH 2 -terminal of canine angiotensinogen revealed the sequence of the first 15 amino acids. Skeggs et al. 21 reported the first 14 amino acids of the amino terminal of horse angiotensinogen, and their sequence was identical to the one reported here. In contrast, angiotensinogens from humans" and rat 17 have a different NH 2 -terminal amino acid sequence. In humans, the 11 amino acid is a valine residue," and in the rat, the 12 amino acid is a tyrosine. 17 Thus, although the first 10 amino acids of angiotensinogen (i.e., angiotensin I) are conserved in many mammalian species, 22 variability in the sequence is frequently found after Position 10.
When analyzed by SDS-PAGE, canine angiotensinogen showed two closely spaced bands with apparent molecular weights of 58,000 and 56,000. Hence, canine angiotensinogen appears to have a molecular weight similar to that for angiotensinogen purified from hog, 23 humans, 24 and rat. 13 n A previous estimation 25 of the molecular weight of canine angiotensinogen yielded a value of 80,000, but the method used for determination was gel filtration and the preparation studied contained 2 /ig of angiotensin I/mg of protein (about 10% angiotensinogen).
Two closely associated molecular weight forms of angiotensinogen have also been found in humans, 24 and rat."• n Studies by Campbell et al. 26 '" in hepatocytes and hepatoma cell lines suggest that varible glycosylation is the basis of the molecular weight heterogeneity of angiotensinogen. Moreover, the molecular weight heterogeneity of angiotensinogen does not appear to be due to variations in its amino acid sequence, since this protein appears to be encoded by a single gene in the rat 28 and human 29 genomes.
Chromatofocusing and analytical isoelectric focusing revealed four isoforms of canine angiotensinogen. Isoelectric heterogeneity has also been found in rat, 13 ' " human, 18 and rabbit 20 angiotensinogens. While both chromatofocusing and isoelectric focusing showed four isoforms of canine angiotensinogen, the isoelecric points obtained by the latter technique were considerably higher than the pH at which angiotensinogen eluted from the Mono P column and more in agreement with values obtained in other species. 13 This finding indicates that during chromatofocusing the different isoforms of angio- tensinogen eluted at a lower pH than their isoelectric points.
The isoelectric distribution of the two molecular weight forms of canine angiotensinogen closely resembles that of rat angiotensinogen. 13 ' n The higher molecular weight angiotensinogen (58,000) showed more acidic isoelectric points than the lower molecular weight angiotensinogen (56,000). The exact origin of the isoelectric heterogeneity of angiotensinogen remains unresolved. Although isoelectric heterogeneity of glycoproteins is frequently due to differences in sialic acid content, neuraminidase treatment of angiotensinogen has been reported both to decrease 30 and to have little effect 13 ' 3I on its isoelectric heterogeneity.
The particular functions of the different molecular size and isoelectric forms of angiotensinogen are unknown. Since the purification procedure described here allows separate isolation of four isoelectric forms, it may provide a necessary initial step to the study of their function.
